Biotech Top Losers: Geron Corporation (NASDAQ:GERN), Synta Pharmaceuticals (NASDAQ:SNTA), Northwest Biotherapeutics (NASDAQ:NWBO), AEterna Zentaris (NASDAQ:AEZS)

Geron Corporation (NASDAQ:GERN) said the US Food and Drug Administration ordered a halt to trials of a cancer drug over concerns about potential liver damage. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The beta of … Continue reading Biotech Top Losers: Geron Corporation (NASDAQ:GERN), Synta Pharmaceuticals (NASDAQ:SNTA), Northwest Biotherapeutics (NASDAQ:NWBO), AEterna Zentaris (NASDAQ:AEZS)

Biotech Stocks Touching New Highs: Oncothyreon (NASDAQ:ONTY), IGI Laboratories (NYSEMKT:IG), TG Therapeutics (NASDAQ:TGTX), Receptos Inc. (NASDAQ:RCPT)

4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development. Oncothyreon Inc. (USA) (NASDAQ:ONTY) stock performance was 1.92% in last session and finished the day at $3.72. Traded volume was 1.16 million shares in the last session and the average volume of the stock remained 904,463.00 … Continue reading Biotech Stocks Touching New Highs: Oncothyreon (NASDAQ:ONTY), IGI Laboratories (NYSEMKT:IG), TG Therapeutics (NASDAQ:TGTX), Receptos Inc. (NASDAQ:RCPT)

Biopharmaceutical giant Oxigene Inc (NASDAQ:OXGN) y reported its experimental drug Zybrestat, combined with Roche’s cancer drug Avastin, significantly slowed progression of recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) stock performance was 77.27% in last session and finished the day at $4.29. Traded volume was 29,290,814 million shares in the last session and the average volume of the stock remained 569.72 million shares. The beta of the … Continue reading Biotech Top Gainers: OXiGENE Inc (NASDAQ:OXGN), Cell Therapeutics Inc (NASDAQ:CTIC), Arca Biopharma Inc (NASDAQ:ABIO), NPS Pharmaceuticals (NASDAQ:NPSP)

Marina Biotech, Inc. (OTCMKTS:MRNA) illustrated a similar run of events, as it reinvigorated its PR activity in the new year and shot upwards as it received a patent protection for one of its therapies. MRNA is back at $1.38, after it slumped for a while following a temporary peak at $1.70. Marina Biotech, Inc. (OTCMKTS:MRNA) stock performance was 16.67% in last session and finished the … Continue reading Biotech Most Volatile: Marina Biotech (OTCMKTS:MRNA), Onconova Therapeutics (NASDAQ:ONTX), OXiGENE Inc (NASDAQ:OXGN), Oragenics Inc (NYSEMKT:OGEN)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax personalized immune therapies for solid tumour cancers, has received approval from the Paul Ehrlich Institute (PEI- the FDA of Germany) of a “Hospital Exemption” early access programme under Section 4b of the German Drug Law. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 16.93% in last session and finished the day at $9.18. Traded volume was 8,391,894 … Continue reading Biotech Unusual Volume: Northwest Biotherapeutics (NASDAQ:NWBO), La Jolla Pharmaceutical Company (NASDAQ:LJPC), OXiGENE (NASDAQ:OXGN), Tengion (OTCMKTS:TNGN)